NX-13 is a first-in-class, orally active and gut-restricted agent that selectively targets and activates the NLRX1 pathway to induce immunometabolic changes. NX-13 results in lower inflammation and responses in inflammatory bowel disease. NX-13 can be used for the research of crohn’s disease and ulcerative colitis[1][2].

NX-13 (0, 500, or 1000 mg/kg; oral gavage; 7 days) reduces ALP levels[2].NX-13 (1 and 10 mg/kg; oral gavage; 0~24 hours) reaches the distal gastrointestinal tract[2].

2389235-01-0

C24H21N3O3

399.44

NX-13

DMSO:135 mg/mL (337.97 mM),Need ultrasonic
Powder: -20°C for 3 years
In solvent: -80°C for 2 years